[go: up one dir, main page]

DK2044950T3 - Svækkede VIF-DNA-immuniseringskassetter til genetiske vacciner - Google Patents

Svækkede VIF-DNA-immuniseringskassetter til genetiske vacciner

Info

Publication number
DK2044950T3
DK2044950T3 DK08075892.3T DK08075892T DK2044950T3 DK 2044950 T3 DK2044950 T3 DK 2044950T3 DK 08075892 T DK08075892 T DK 08075892T DK 2044950 T3 DK2044950 T3 DK 2044950T3
Authority
DK
Denmark
Prior art keywords
cassettes
dna immunization
genetic vaccines
attenuated
vif dna
Prior art date
Application number
DK08075892.3T
Other languages
English (en)
Inventor
Velpandi Ayyavoo
Thanadavarayan Nagashunmugam
David B Weiner
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of DK2044950T3 publication Critical patent/DK2044950T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK08075892.3T 1997-09-18 1998-09-18 Svækkede VIF-DNA-immuniseringskassetter til genetiske vacciner DK2044950T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5928397P 1997-09-18 1997-09-18
US6017297P 1997-09-26 1997-09-26
EP98946105A EP1015009A4 (en) 1997-09-18 1998-09-18 GENETIC MATERIAL IN THE FORM OF MITIGATED IMMUNIZATION CASSETTES BASED ON LIVER DNA FOR GENETIC VACCINES

Publications (1)

Publication Number Publication Date
DK2044950T3 true DK2044950T3 (da) 2012-09-17

Family

ID=26738576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08075892.3T DK2044950T3 (da) 1997-09-18 1998-09-18 Svækkede VIF-DNA-immuniseringskassetter til genetiske vacciner

Country Status (9)

Country Link
US (2) US7151172B1 (da)
EP (2) EP1015009A4 (da)
JP (2) JP4418101B2 (da)
AU (1) AU752725B2 (da)
CA (1) CA2304125A1 (da)
DK (1) DK2044950T3 (da)
ES (1) ES2389519T3 (da)
PT (1) PT2044950E (da)
WO (1) WO1999013896A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97800C2 (uk) 2006-03-10 2012-03-26 Пептселл Лімітед Пептидні послідовності і композиції
EP3489251B1 (en) 2006-07-28 2021-03-17 The Trustees of the University of Pennsylvania Hiv consensus proteins and vaccines made therefrom
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3250802B2 (ja) 1989-03-21 2002-01-28 バイカル・インコーポレイテッド 脊椎動物における外因性ポリヌクレオチド配列の発現
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
WO1993017706A1 (en) 1992-03-11 1993-09-16 Agracetus, Inc. Genetic vaccine for immunodeficiency viruses
WO1993023552A1 (en) 1992-05-21 1993-11-25 Government Of The United States As Represented By Secretary Department Of Health And Human Services Targeting gene expression to living tissue using jet injection
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
WO1995005851A1 (en) 1993-08-20 1995-03-02 St. Luke's-Roosevelt Hospital Center HIV vif-RELATED COMPOSITIONS, AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF

Also Published As

Publication number Publication date
US20070106062A1 (en) 2007-05-10
EP2044950A2 (en) 2009-04-08
US8183352B2 (en) 2012-05-22
WO1999013896A1 (en) 1999-03-25
AU752725B2 (en) 2002-09-26
ES2389519T3 (es) 2012-10-26
EP1015009A4 (en) 2001-11-07
JP2001516566A (ja) 2001-10-02
AU9319098A (en) 1999-04-05
JP4749481B2 (ja) 2011-08-17
CA2304125A1 (en) 1999-03-25
EP1015009A1 (en) 2000-07-05
US7151172B1 (en) 2006-12-19
JP2010001290A (ja) 2010-01-07
EP2044950B1 (en) 2012-06-27
PT2044950E (pt) 2012-09-18
JP4418101B2 (ja) 2010-02-17
EP2044950A3 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
DK2044950T3 (da) Svækkede VIF-DNA-immuniseringskassetter til genetiske vacciner
NO2022060I1 (no) Aflibercept
DE69828517D1 (de) Methode zur dns-isolierung.
DK1011309T3 (da) Fremgangsmåde til tilvejebringelse af forøget fotosyntese
DK0519338T3 (da) Forbedrede fremgangsmåder til nukleinsyreamplifikation
NO20003302D0 (no) Vaksine
EP0809513A4 (en) NUCLEIC ACID OF RECOMBINANT ENCAPSIDE POLIOVIRUS
DE69822614D1 (de) Dna kapillare
DK0871767T3 (da) Fremgangsmåde til amplificering af specifikke nucleinsyresekvenser
DE69934583D1 (de) Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
FR2776928B1 (fr) Vaccins adn adjuves
EP0627935A4 (en) IMPROVED VACCINE AGAINST BRUCELLA ABORTU.
EP1397043A4 (en) GENETIC IMMUNIZATION PROCESSES
FI980463L (fi) Itsereplikoituva vektori DNA-immunisaatiota varten HIV:tä vastaan
ITPN950042A0 (it) Sistema di controllo per bruciatore catalitico
DK0978485T3 (da) Føderørsløftesystem til forherd
DK98594A (da) Udtrækssystem til læssebagsmæk
DE59700382D1 (de) Indiumhaltiger, oxidkeramischer Thermistor
DK0942704T3 (da) Underlag til patient
EP1210364A4 (en) VACCINE ANTIGENS FROM MORAXELLA
ITPD940081A0 (it) Dispositivo di sostegno per piastre radianti.
IT1310192B1 (it) Metodo e mezzi per il controllo di sicurezza di bruciatori.
NL1002549C1 (nl) Afstandhouder voor dakgoten.
IT1293038B1 (it) Sistema divisorio per edifici
IT1298764B1 (it) Sistema di controllo dentale